1. Home
  2. EEA vs IRD Comparison

EEA vs IRD Comparison

Compare EEA & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EEA
  • IRD
  • Stock Information
  • Founded
  • EEA 1986
  • IRD 2018
  • Country
  • EEA Germany
  • IRD United States
  • Employees
  • EEA N/A
  • IRD N/A
  • Industry
  • EEA Trusts Except Educational Religious and Charitable
  • IRD
  • Sector
  • EEA Finance
  • IRD
  • Exchange
  • EEA Nasdaq
  • IRD NYSE
  • Market Cap
  • EEA 57.7M
  • IRD 62.0M
  • IPO Year
  • EEA N/A
  • IRD N/A
  • Fundamental
  • Price
  • EEA $9.86
  • IRD $0.95
  • Analyst Decision
  • EEA
  • IRD Strong Buy
  • Analyst Count
  • EEA 0
  • IRD 3
  • Target Price
  • EEA N/A
  • IRD $6.33
  • AVG Volume (30 Days)
  • EEA 9.2K
  • IRD 2.4M
  • Earning Date
  • EEA 01-01-0001
  • IRD 08-15-2025
  • Dividend Yield
  • EEA 1.92%
  • IRD N/A
  • EPS Growth
  • EEA N/A
  • IRD N/A
  • EPS
  • EEA N/A
  • IRD N/A
  • Revenue
  • EEA N/A
  • IRD $13,651,000.00
  • Revenue This Year
  • EEA N/A
  • IRD $51.41
  • Revenue Next Year
  • EEA N/A
  • IRD $68.84
  • P/E Ratio
  • EEA N/A
  • IRD N/A
  • Revenue Growth
  • EEA N/A
  • IRD N/A
  • 52 Week Low
  • EEA $7.45
  • IRD $0.65
  • 52 Week High
  • EEA $9.26
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • EEA 50.51
  • IRD N/A
  • Support Level
  • EEA $9.90
  • IRD N/A
  • Resistance Level
  • EEA $10.18
  • IRD N/A
  • Average True Range (ATR)
  • EEA 0.12
  • IRD 0.00
  • MACD
  • EEA -0.04
  • IRD 0.00
  • Stochastic Oscillator
  • EEA 3.03
  • IRD 0.00

About EEA The European Equity Fund Inc.

European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: